Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.4298
-0.0400 (-8.51%)
Oct 30, 2026, 11:52 AM EDT - Market open
Humacyte Revenue
Humacyte had revenue of $406.00K in the quarter ending June 30, 2026, with 34.88% growth. This brings the company's total for the last twelve months to $2.12M, up 159.29% year-over-year. In the year 2025, Humacyte had annual revenue of $2.04M. That makes Humacyte the 42,259th largest company in the world by revenue and 5,737th in the United States.
Revenue (ttm)
$2.12M
Revenue Growth
+159.29%
P/S Ratio
55.26
Revenue / Employee
$11,527
Employees
184
Market Cap
119.40M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cue Biopharma | 37.66M |
| Foghorn Therapeutics | 36.74M |
| Innate Pharma | 11.21M |
| Armata Pharmaceuticals | 5.54M |
| NRx Pharmaceuticals | 3.39M |
| Spruce Biosciences | 697.00K |
| Outlook Therapeutics | -1.16M |
HUMA News
- 2 days ago - Humacyte issued new U.S. patent covering Symvess - TheFly
- 2 days ago - Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues - GlobeNewsWire
- 7 days ago - Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner - GlobeNewsWire
- 15 days ago - Humacyte says hospitals ordering Symvess rose 44% in Q3 to 49 - TheFly
- 15 days ago - Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals - GlobeNewsWire
- 23 days ago - Humacyte initiated with an Equal Weight at Barclays - TheFly
- 4 weeks ago - Humacyte announces addition of Coward, Kuznik to board - TheFly
- 4 weeks ago - Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik - GlobeNewsWire